Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Cycling does not adversely affect sexual, urinary function in females

07 Apr 2018
A study suggests that working out intensely for a minute three times a week will provide the same benefits as a longer, endurance training.

Female cyclists do not have significantly worse urinary or sexual function compared with other athletes, a recent study has shown. However, other genitourinary conditions, such as saddle sores and genital numbness, are associated with cycling and may lead to sexual dysfunction.

Using Facebook advertisements and outreach to sporting clubs, researchers recruited 1,656 low-intensity cyclists and 409 high-intensity cyclists, who were asked to accomplish a survey. Swimmers and runners (n=1,053) were recruited as noncyclist controls. Study outcomes included responses to different validated questionnaires, such as the Female Sexual Function Index (FSFI) and the American Urological Association Symptom Index.

Interestingly, both high-intensity (mean score, 23.1 points; p<0.001) and low-intensity (mean score, 22.6 points; p<0.001) cyclists had significantly higher mean FSFI scores than noncyclists (mean score, 20.8). Results in the arousal, lubrication, orgasm and satisfaction domains were significantly better for both cyclist groups.

The high-intensity and low-intensity cyclist groups also had significantly lower odds of reporting sexual dysfunction than controls (odds ratio [OR], 0.6; 0.5–0.8; p<0.001 and OR, 0.8; 0.6–0.9; p<0.001, respectively).

After multivariable adjustment, statistical significance was attenuated such that low-intensity and high-intensity cyclists had mean FSFI scores similar to noncyclist controls. High-intensity cyclists remained significantly less likely to report sexual dysfunction than controls (OR, 0.7; 0.6–0.95; p=0.02).

In contrast, both cyclist respondent groups showed significantly higher odds of reporting previous urinary tract infection, perineal numbness and saddle sores, as compared with swimmers or runners.

Across all analyses performed, no significant differences in urinary symptoms were reported across all groups.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.